Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14420046 | 0.92 | HDAC6 (0.67) | MAPTKMT2AMEN1ALDH1A1SLC13A5 | |
| SCHEMBL172079 | 0.89 | ALDH1A1 (0.68) | MAPTKMT2AMEN1ALDH1A1SLC13A5 | |
| SCHEMBL23747548 | 0.88 | RAB9A (0.66) | MAPTKMT2AMEN1POLBNPC1 | |
| Hydrochloric Acid SCHEMBL30164247 | 0.88 | ALDH1A1 (0.67) | MAPTKMT2AMEN1ALDH1A1SLC13A5 | |
| SCHEMBL13745754 | 0.86 | ALDH1A1 (0.62) | KMT2AMEN1ALDH1A1SLC13A5POLB | |
| SCHEMBL28472104 | 0.84 | ALDH1A1 (0.62) | MAPTKMT2AALDH1A1USP2HPGD | |
| SCHEMBL3349120 | 0.83 | ALDH1A1 (0.67) | MAPTKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL23747596 | 0.83 | RAB9A (0.63) | KMT2AMEN1ALDH1A1USP2HPGD | |
| SCHEMBL23747820 | 0.83 | RAB9A (0.63) | KMT2AMEN1ALDH1A1USP2HPGD | |
| SCHEMBL23774080 | 0.82 | ALDH1A1 (0.64) | KMT2AMEN1ALDH1A1USP2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140371198-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2014-12-18 | — | — | US | disclosed |
| US-8759334-B2 | Compounds useful for the treatment of metabolic and inflammatory diseases | GALAPAGOS NV (BE) | 2014-06-24 | — | — | US | disclosed |
| EP-2665704-A1 | AZETIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | Galapagos NV (BE) | 2013-11-27 | — | — | EP | disclosed |
| US-20130303515-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2013-11-14 | — | — | US | disclosed |
| CN-103328442-A | Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases | GALAPAGOS NV | 2013-09-25 | — | — | CN | disclosed |
| WO-2012098033-A1 | AZETIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371198-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GOT2, GPR119, PC | MAPT 4336/4885KMT2A 3849/4885MEN1 3061/4885 |
| US-20130303515-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GOT2, GPR119, PC | MAPT 4336/4885KMT2A 3849/4885MEN1 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.